This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wünschmann, S.
Right arrow Articles by Stapleton, J. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wünschmann, S.
Right arrow Articles by Stapleton, J. T.

 Previous Article  |  Next Article 

Journal of Virology, November 2000, p. 10055-10062, Vol. 74, No. 21
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Characterization of Hepatitis C Virus (HCV) and HCV E2 Interactions with CD81 and the Low-Density Lipoprotein Receptor

Sabina Wünschmann, Jheem D. Medh, Donna Klinzmann, Warren N. Schmidt, and Jack T. Stapleton*

Department of Internal Medicine, Veterans Administration Medical Center and University of Iowa College of Medicine, Iowa City, Iowa

Received 16 March 2000/Accepted 26 July 2000


    ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

Hepatitis C virus (HCV) or HCV-low-density lipoprotein (LDL) complexes interact with the LDL receptor (LDLr) and the HCV envelope glycoprotein E2 interacts with CD81 in vitro. However, E2 interactions with LDLr and HCV interactions with CD81 have not been clearly described. Using sucrose gradient-purified low-density particles (1.03 to 1.07 g/cm3), intermediate-density particles (1.12 to 1.18 g/cm3), recombinant E2 protein, or control proteins, we assessed binding to MOLT-4 cells, foreskin fibroblasts, or LDLr-deficient foreskin fibroblasts at 4°C by flow cytometry and confocal microscopy. Viral entry was determined by measuring the coentry of alpha -sarcin, a protein synthesis inhibitor. We found that low-density HCV particles, but not intermediate-density HCV or controls bound to MOLT-4 cells and fibroblasts expressing the LDLr. Binding correlated with the extent of cellular LDLr expression and was inhibited by LDL but not by soluble CD81. In contrast, E2 binding was independent of LDLr expression and was inhibited by human soluble CD81 but not mouse soluble CD81 or LDL. Based on confocal microscopy, we found that low-density HCV particles and LDL colocalized on the cell surface. The addition of low-density HCV but not intermediate-density HCV particles to MOLT-4 cells allowed coentry of alpha -sarcin, indicating viral entry. The amount of viral entry also correlated with LDLr expression and was independent of the CD81 expression. Using a solid-phase immunoassay, recombinant E2 protein did not interact with LDL. Our data indicate that E2 binds CD81; however, virus particles utilize LDLr for binding and entry. The specific mechanism by which HCV particles interact with LDL or the LDLr remains unclear.


    INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

Hepatitis C virus (HCV) infection is a major cause of chronic liver disease worldwide. Approximately 85% of people infected with HCV remain persistently viremic, and approximately 20% to 50% of these individuals ultimately develop cirrhosis (12, 21, 50). Of those with HCV-related cirrhosis, approximately 5% develop hepatocellular carcinoma (21, 50). In the United States, an estimated 4 million people are infected, and HCV is the leading cause of liver transplantation (21). Extrahepatic manifestations, including cryoglobulinemia and B-lymphocyte proliferative disorders, which are characterized by polyclonal B-cell activation and autoantibody production, are also associated with HCV infection (3, 13, 14, 39). Hepatocytes represent the primary site of HCV replication in vivo. Although explanted peripheral blood mononuclear cells (PBMCs) contain HCV RNA (4, 30, 40), it is unclear if HCV replication occurs in PBMCs in vivo (1, 16, 23, 52). No efficient cell culture system has been described for HCV, but in vitro studies have shown that several human cells including primary PBMC cultures (10) and cell lines of hepatocyte and lymphoid origin (42-45) are permissive for HCV replication.

Currently, the mechanism of HCV cell entry is not clear. Two cell surface receptors interact with HCV or HCV E2 protein in vitro, leading to speculation that either may represent the HCV cellular receptor (2, 15, 29, 35). The HCV envelope glycoprotein E2 was shown to specifically bind to human CD81 (15, 35). CD81 is a member of the tetraspanin superfamily of cell surface molecules and is expressed on virtually all nucleated cells (24). It is highly expressed on germinal-center B cells (15, 26, 35), although the level of expression within a single tissue varies during development and in response to cellular activation (24). Expression of CD81 on B cells was found to be critical for inducing optimal interleukin-4 and antibody production during T helper 2 (Th2) responses, suggesting that CD81 may interact with a ligand on T-helper cells (25). As part of a complex on B cells that includes CD19, CD21, and Leu13, CD81 can provide costimulatory signals that lower the threshold required for B cells to respond to antigen (26). Therefore, it was hypothesized that binding of HCV to CD81 on B cells in vivo lowers the activation threshold of these cells, facilitating the production of autoantibodies found in HCV-associated cryoglobulinemia (15, 35, 39). These studies suggested that E2 binding to CD81 may be responsible for the binding of HCV to target cells in vivo. However, only one study provides any evidence that viral particles bind CD81 in vitro or in vivo (35).

Thomssen et al. (48, 49) and others (36, 55) identified an association between HCV and low density lipoproteins (LDL) in human sera and subsequently demonstrated an interaction between HCV or HCV-LDL complexes with the cellular low-density lipoprotein receptor (LDLr). Seipp et al. demonstrated that persistent HCV replication occurred in cell lines of hepatocyte origin if they were maintained under conditions that upregulated LDLr expression (42). More recent studies demonstrated that HCV did not bind LDLr-deficient fibroblasts but that the expression of recombinant human LDLr in these cells promoted virus binding (29). Recently the LDLr was reported to promote viral entry for several members of the flavivirus family, including HCV and GB virus type C (also called hepatitis G virus) (2). Interactions between the HCV E2 protein or other viral proteins with either LDL or the LDLr have not been described.

The purpose of this study was to characterize interactions of both HCV and the viral envelope protein E2 with the LDLr and CD81. We used a lymphoid cell line (MOLT-4) which had previously been shown to support HCV replication in vitro (44) and human fibroblast cell lines with and without the LDLr to evaluate HCV binding. Our data provide further evidence of an association between HCV and LDL in human plasma and demonstrate that the LDLr is primarily responsible for HCV binding and entry. Although there is clearly specific binding of the envelope glycoprotein E2 to human CD81, our data do not suggest that CD81 is involved in cell binding or entry of infectious HCV particles.

(This work was presented in part at the IX International Symposium on HCV and Related Flaviviruses, Bethesda, Md., 6 June 1999.)


    MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

HCV preparations. Plasma was obtained from patients with HCV-related chronic liver disease. Plasma samples were tested by a commercially available HCV RNA quantitation method as previously described (Roche Monitor assay) (46). All patients tested positive for HCV antibodies (EIA 2.0 antibody tests; Abbott Laboratories, North Chicago, Ill.) and for HCV RNA by reverse transcription-PCR (RT-PCR) as previously described (38). Plasma was prepared from anticoagulated blood samples by centrifugation at 600 × g for 15 min, and HCV particles were separated by sucrose gradient centrifugation as previously described (54, 55). Gradient fractions were evaluated for HCV RNA by an in-house RT-PCR method as previously described (46). Fractions containing HCV low-density particles (1.04 to 1.07 g/ml) and intermediate-density particles (1.12 to 1.18 g/ml) were pooled, pelleted at 156,000 × g for 16 h at 4°C, and resuspended in phosphate-buffered saline (PBS), and aliquots were frozen at -80°C. RNA was extracted from pelleted fractions, and the relative end-point dilution dilution titer of HCV RNA was measured by RT-PCR (56). Negative-control preparations (mock) were simultaneously prepared using HCV antibody and HCV RNA-negative plasma in sucrose gradients, and fractions of corresponding density were pelleted and stored. This study was approved by the University of Iowa Institutional Review Board, and all subjects provided informed consent.

Proteins and antibodies. Purified recombinant HCV envelope glycoprotein E2 (Ala 384 to Lys 715) and the nonstructural proteins NS3/NS4 (Asp 1569 to Pro 1931) expressed in CHO cells were obtained from Austral Biologicals (San Remo, Calif.). Human and mouse soluble CD81 was kindly provided by Shoshana Levy (Stanford University). LDL was obtained from Sigma (St. Louis, Mo.).

Anti-human LDLr monoclonal antibody (MAb) (clone C7) and anti-human LDL MAb (clone 4G3) were used in the studies (28, 51). Polyclonal goat anti-human LDL was obtained from Sigma. Anti-human CD81 MAb (clone JS64) was obtained from RD Inc. (Flanders, NJ). Anti-HCV E2 MAb was obtained from Austral Biologicals. Nonspecific mouse immunoglobulin G (IgG1) (Zymed, San Francisco, Calif.) was used as an isotype control. Anti-HCV polyclonal serum was obtained from an HCV-seropositive patient who was HCV RNA negative due to interferon therapy (38, 46). The negative control serum used in HCV-binding studies was obtained from an HCV RNA- and antibody-negative individual. Mouse IgG binding to cells was detected using an anti-mouse IgG (labeled with either Oregon green or Texas red), and human IgG binding to cells was detected with anti-human IgG labeled with Oregon green (Molecular Probes, Eugene, Oreg.). Alkaline phosphatase-labeled antispecies antibodies (Sigma) were used for solid-phase assays.

Cell lines. MOLT-4 cells, a CD4+ T lymphoblastoid cell line, and mouse L cells were obtained from the American Type Culture Collection (Manassas, Va.). Human foreskin fibroblasts (FSF) and LDLr-deficient foreskin fibroblasts from a patient with familial hypercholesterolemia were also used in this study as described previously (20). MOLT-4 cells were cultured in RPMI 1640, and mouse L cells and human fibroblasts were cultured in Dulbecco modified Eagle medium. Media were supplemented with 10% fetal calf serum (FCS), 100 U of penicillin per ml, 100 µg of streptomycin sulfate per ml, and 2 mM L-glutamine. In some experiments, LDLr expression was induced by incubating cells for 48 h in RPMI 1640 or Dulbecco modified Eagle medium without FCS or in medium containing 10% lipoprotein-deficient human serum (LPDS), prepared as previously described (20).

RNA extraction and RT-PCR. HCV RNA was isolated from patient plasma or gradient fractions using the RNA extraction method described by Chomczynski and Sacchi (8). Oligonucleotide primers for amplification of the HCV 5' nontranslated region were used as described previously (38). DNA products (250 bp) were separated on 1.5% agarose gels and visualized by ethidium bromide staining.

HCV particle-binding assay. MOLT-4 cells were washed in PBS containing 1% LPDS and 0.05% NaN3 and resuspended in either the HCV or mock-virus preparations. The cells were incubated for 60 min at 4°C, washed with PBS, and incubated in PBS plus 10% goat serum for 30 min at 4°C to prevent nonspecific antibody binding. The cells were washed and incubated with HCV antiserum or control serum (1:100 in PBS) for 60 min at 4°C. Antibody binding was detected using goat anti-human IgG-Oregon green (10 µg/ml) for 45 min at 4°C. The cells were washed twice, fixed in PBS containing 4% paraformaldehyde, and analyzed using flow cytometry (FACScan; Becton Dickinson). In cases where the fluorescence of the isotype control was higher than that of the mock-virus control, the specific binding of HCV was normalized by subtracting the value of the isotype control.

Solid-phase immunoassay. Nitrocellulose (Schleicher & Schuell, Keene, N.H.) was placed into 48-well plates, and proteins of interest (10 µg/ml) were directly applied to the membrane and blocked with 5% nonfat dry milk in PBS for 30 min at room temperature. Membranes were subsequently incubated with either LDL, E2, or soluble CD81 (10 µg/ml in PBS) for 45 min at room temperature followed by three washes in PBS. Protein-protein interactions were detected with polyclonal or monoclonal anti-E2 and anti-LDL monoclonal antibodies at 10 µg/ml followed by incubation with alkaline phosphatase (AP)-labeled anti-mouse IgG or anti-human IgG. AP was detected with freshly prepared 5-bromo-4-chloro-3-indolyl phosphate-nitroblue tetrazolium substrate.

Confocal microscopy. MOLT-4 cells were incubated in RPMI 1640 without FCS for 48 h to upregulate expression of the LDL receptor. Cells were washed in PBS and incubated with the mock-virus or HCV preparations for 45 min at 4°C. Following two washes in PBS, the cells were incubated for 30 min at 4°C in PBS containing 10% goat serum and were again washed twice in PBS. HCV or LDL binding was detected by simultaneous incubation with human polyclonal anti-HCV serum (1:100) and mouse anti-LDL MAb (10 µg/ml) for 45 min at 4°C, followed by fluorescence-labeled antispecies antibodies (10 µg/ml in PBS). The cells were analyzed for HCV colocalization with LDL by using confocal laser microscopy (Zeiss, Jena, Germany) as previously described (53).

alpha -Sarcin coentry studies. MOLT-4 or mouse L cells (5 × 105) were resuspended with HCV or mock-virus preparations in methionine-deficient medium containing alpha -sarcin. After a 1-h incubation at 37°C, [35S]methionine (Amersham) was added for 15 min. The cells were washed and lysed, and trichloroacetic acid-precipitable counts were measured. For some experiments, MOLT-4 cells were preincubated for 48 h in serum-free RPMI 1640 or in RPMI 1640 containing 10% LPDS. All experiments were performed in duplicate or triplicate and were repeated at least three times.


    RESULTS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

Binding of HCV and HCV-E2 to MOLT-4 cells. To measure HCV binding to cells, plasma from four HCV-infected patients and three controls was fractionated by equilibrium centrifugation on sucrose gradients and HCV RNA was detected in low-density fractions (1.03 to 1.08 g/ml) and in intermediate-density fractions (1.12 to 1.18 g/ml). The concentration of HCV RNA in two of these patients was greater than 106 genome equivalents per ml of plasma. Previous studies demonstrated that low-density HCV particles are associated with infectivity (6, 19) and are thought to represent the complete virion whereas the intermediate-density particles appear to represent nucleocapsids or virus-immune complexes (18, 19, 55). In addition to infectious HCV, LDL is found in low-density fractions of 1.006 to 1.063 g/cm3 and in association with HCV particles (48, 49).

To detect the binding of HCV to MOLT-4 cells, pelleted virus or the corresponding pellet from HCV-negative plasma fractions (Mock) were added to MOLT-4 T cells and virus was identified using human HCV antiserum followed by a fluorescence-labeled secondary antibody. All incubations were performed at 4°C to prevent internalization and receptor cycling. The cells were fixed and examined for cell-bound fluorescence by flow cytometry or confocal microscopy. Low-density HCV particles bound MOLT-4 cells, but intermediate-density HCV particles and Mock fractions did not. The extent of intermediate-density HCV particle binding to MOLT-4 cells was lower than that of the Mock control by this fluorescence-based method (Fig. 1). The relative concentration of HCV RNA in the intermediate-density particles was 10-fold higher than that in the low-density peak when measured by end-point dilution (data not shown). Thus, the difference in binding between the low-density and intermediate-density particles cannot be explained by differences in HCV concentration. Using flow cytometry, we also examined the binding of the HCV envelope glycoprotein E2 to MOLT-4 cells. The HCV nonstructural proteins NS3/NS4 served as the negative control. The results indicated that more than 90% of cells bound HCV-E2 (Fig. 1C).


View larger version (9K):
[in this window]
[in a new window]
  		FIG. 1.   HCV and HCV-E2 binding to MOLT-4 cells. HCV low-density particles (A), HCV intermediate-density particles (B), and HCV-E2 (C) were evaluated for binding to MOLT-4 cells (open graphs). Mock sucrose gradient preparations (shaded graphs [A and B]) or the HCV nonstructural protein NS3/NS4 (shaded graph [C]) served as negative controls. Cell-bound virus or HCV-E2 protein was visualized with HCV-specific antiserum and anti-human IgG Oregon green (FITC).

To determine if binding of the low-density HCV particles was correlated with expression of the LDL receptor or CD81, we first examined the regulation of both receptors in different stages of the cell cycle (Fig. 2). MOLT-4 cells were stained for LDLr and CD81 at various time points following cell culture passage. Nonspecific binding was ruled out using a mouse IgG1 isotype control antibody. CD81 was expressed at a constant level (98%), and expression was independent of the cell cycle. LDLr expression (6%) was significantly lower in cells maintained for 48 h in RPMI 1640 containing FCS (Fig. 2A) than in cells grown in lipoprotein-deficient medium for 24 h (52%) or 48 h (91%) (Fig. 2B and C). HCV and HCV-E2 binding was evaluated using cells that expressed low or high densities of LDLr (Table 1). In three independent experiments, HCV binding correlated with LDLr expression, resulting in up to a twofold increase in HCV binding to cells with high levels of LDLr. In contrast to whole virus, the viral envelope glycoprotein E2 bound more efficiently to cells and did not vary significantly in relation to LDLr expression. Upregulation of the LDLr actually resulted in a slight decrease in binding of E2 to MOLT-4 cells (80% versus 98%). The relationship between LDLr expression and HCV low-density particle binding was also shown by virus binding to normal FSF but not to LDLr-deficient FSF (Fig. 3).


View larger version (22K):
[in this window]
[in a new window]
  		FIG. 2.   Flow cytometric characterization of CD81 and LDLr expression on MOLT-4 cells. MOLT-4 cells were grown for 48 h in lipoprotein-rich medium (A) or for 24 h (B) or 48 h (C) in lipoprotein-deficient medium. Background fluorescence was measured with an irrelevant isotype-matched control MAb. CD81 expression was measured with JS64 MAb, and LDLr expression was measured with C7 MAb. Cell-bound antibodies were detected with anti-mouse IgG Oregon green (FITC).

                              
View this table:
[in this window]
[in a new window]
  		TABLE 1.   HCV and E2 binding to MOLT-4 cells with low or high levels of LDLr expression



View larger version (14K):
[in this window]
[in a new window]
  		FIG. 3.   HCV binding to FSF. HCV low-density particles were evaluated for binding to FSF (A) and LDLr-deficient FSF (B). Mock sucrose gradient preparations (shaded graphs) served as negative controls. Cell-bound virus was visualized with HCV specific antiserum and anti-human IgG Oregon green (FITC).

To determine the specificity of HCV and HCV-E2 binding to MOLT-4 cells, competition experiments using LDL (0.05 to 0.5 mg/ml) were performed. HCV binding was inhibited by LDL at 0.5 mg/ml, whereas the binding of E2 was unaffected (Table 2). In contrast, human but not mouse CD81 completely blocked E2 binding to MOLT-4 cells. The specific binding of HCV E2 to human CD81 was further demonstrated using solid-phase immunoassays (Fig. 4). E2 reproducibly bound to human CD81 but not to mouse CD81 or an irrelevant peptide control.

                              
View this table:
[in this window]
[in a new window]
  		TABLE 2.   Inhibition of HCV and HCV E2 protein binding to MOLT-4 cells by human soluble CD81, mouse soluble CD81, and LDL



View larger version (23K):
[in this window]
[in a new window]
  		FIG. 4.   Specificity of HCV-E2 interactions with human CD81. Soluble human or mouse CD81 (10 µg/ml) applied to nitrocellulose was incubated with HCV-E2 (10 µg/ml). E2 applied to nitrocellulose served as the positive control, and an irrelevant control peptide served as the negative control. Interactions of E2 with each protein were detected with anti HCV-E2 MAb, anti-mouse IgG-AP, and 5-bromo-4-chloro-3-indolyl phosphate-nitroblue tetrazolium substrate.

HCV, HCV-E2, and LDL interactions. To determine if HCV was associated with LDL, we evaluated MOLT-4 cells by confocal microscopy following incubation with low-density HCV particles at 4°C. LDL was detected by incubation with mouse anti-LDL followed by a secondary Texas red-labeled antibody, and HCV was identified using HCV antiserum followed by a secondary Oregon green-labeled antibody. MOLT-4 cells incubated with the Mock preparation and stained for HCV and LDL showed only detection of LDL (Fig. 5A). Cells incubated with HCV and HCV E2 protein stained only for HCV showed green fluorescent surface binding (Fig. 5B and C). Colocalization of LDL and HCV was demonstrated in cells incubated with HCV (Fig. 5D to F) but not in cells incubated with the Mock control (Fig. 5A). The LDL concentrations in the original HCV and Mock plasma samples were similar (104 and 105 mg/dl, respectively).


View larger version (13K):
[in this window]
[in a new window]
  		FIG. 5.   Immunofluorescence detection of HCV, LDL, and HCV-E2 on MOLT-4 cells. MOLT-4 cells were incubated with low-density Mock fractions (A), low-density HCV (B and D to F), or HCV-E2 (10 µg/ml) (C) at 4°C. HCV and HCV-E2 were localized with human HCV-specific antiserum followed by anti-human IgG-Oregon green (B, C, E, and G), whereas LDL was localized with mouse anti-LDL MAb and anti-mouse IgG-Texas red (A, D, and F). Incubation of cells with HCV low-density particles followed by dual staining showed colocalization of LDL (D) and HCV (E) as yellow fluorescence in the overlay (F). Dual staining of MOLT-4 cells incubated with Mock sucrose gradient fractions is shown in panel A.

To determine if the HCV-LDL interactions involved E2, HCV-E2 binding to the LDL was assessed using solid-phase immunoassays (Fig. 6). HCV E2, the nonstructural proteins NS3/NS4, human or mouse CD81, and a goat anti-LDL-specific antibody (positive control) were each applied to nitrocellulose and incubated with LDL. Bound LDL was detected with a mouse anti-LDL antibody followed by an AP-labeled anti-mouse IgG antibody and nitroblue tetrazolium substrate. LDL was detected only in the anti-LDL control, and no LDL binding was detected using CD81 or E2 proteins.


View larger version (21K):
[in this window]
[in a new window]
  		FIG. 6.   HCV-E2 does not interact with LDL. HCV-E2, HCV NS3/4, human soluble CD81, or mouse soluble CD81 spotted on nitrocellulose were incubated with LDL (10 µg/ml). The positive control consisted of goat-anti LDL polyclonal antibody spotted on nitrocellulose. Interaction of spotted proteins with LDL was detected with mouse anti-LDL MAb and anti-mouse IgG AP followed by 5-bromo-4-chloro-3-indolyl phosphate-nitroblue tetrazolium substrate. Binding was quantitated by densitometry (AlphaImager 2000; Alpha Innotech Corp., San Leandro, Calif.), and results represent density units × 100.

HCV low-density particles promote coentry of alpha -sarcin. The protein translation inhibitor alpha -sarcin does not enter cells with intact cell membranes (31, 32). Previous studies demonstrated that coentry of alpha -sarcin occurs with binding and penetration of several animal viruses in vitro (11, 31, 32). Depending on the mode of entry, the inhibitor enters the cell via virus-induced changes in membrane permeability or via endocytosis, in which case the inhibitor is set free from the endosome during the uncoating process of the virus (32). To study virus entry, HCV was incubated with MOLT-4 or mouse L cells at 37°C in the presence of alpha -sarcin. Mouse L cells were used as a negative control, since they do not express human CD81 or the human LDL receptor. Cellular protein synthesis was determined by pulsing cells with [35S]methionine and measuring 35S incorporation into cellular proteins. Incubation of MOLT-4 cells with HCV intermediate-density particles (density, 1.12 to 1.16 g/ml) or Mock control fractions did not result in coentry of alpha -sarcin, whereas incubation with HCV low-density particles (1.04 to 1.08 g/ml) resulted in protein synthesis inhibition (P < 0.001, paired t test) (Table 3). Coentry of alpha -sarcin was not seen in mouse L cells incubated with HCV or Mock preparations. As noted above, LDLr expression on MOLT-4 cells was low during log phase and was upregulated during stationary phase or by incubation in LPDS. HCV and alpha -sarcin coentry occurred significantly more when cells were maintained under conditions that upregulated LDLr expression (Table 4). To determine if the alpha -sarcin entry correlated with the concentration of HCV applied to cells, serial twofold dilutions of the HCV (low-density particle) preparation or the control were made prior to incubating the MOLT-4 cells with HCV and alpha -sarcin. Table 5 shows that alpha -sarcin entry was dose dependent and decreased with decreasing concentrations of HCV.

                              
View this table:
[in this window]
[in a new window]
  		TABLE 3.   Coentry of HCV and alpha -sarcin is specific for low-density particlesa


                              
View this table:
[in this window]
[in a new window]
  		TABLE 4.   Coentry of HCV and alpha -sarcin increases with higher levels of LDLr expressiona


                              
View this table:
[in this window]
[in a new window]
  		TABLE 5.   Entry of alpha -sarcin into MOLT-4 cells is dependent on the concentration of low-density HCV particlesa


    DISCUSSION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

The mechanism by which HCV binds to and enters cells appears to be complex. Our data confirm a highly specific interaction between HCV E2 protein and cellular CD81; however, viral particles obtained from patient plasma do not appear to have direct interactions with this cellular receptor. This was demonstrated by showing that both E2 and low-density HCV particles bound to MOLT-4 cells, yet human soluble CD81 only competed for binding with HCV E2 and not with low-density HCV particles. In contrast, LDL inhibited only viral binding and did not inhibit E2 binding. The importance of the LDLr in HCV binding was further demonstrated by increasing viral binding and entry, but not E2 binding, under conditions that led to upregulation of the LDLr.

There are several reports indicating that infectious HCV particles in plasma are associated with beta -lipoproteins and that binding of HCV to the LDLr may be mediated by very low density lipoprotein (VLDL) or LDL (2, 19, 36, 42, 48, 49). Since the HCV preparations used in our experiments are derived from plasma, the low-density particle fractions in our experiments also contain beta -lipoproteins. Our finding that LDL and HCV colocalized on the surface of MOLT-4 cells supports the hypothesis that HCV-LDL interactions occur and that the resulting complex utilizes the LDLr for binding. It is not clear if the intermediate-density fractions in sucrose gradients represent viral nucleocapsids (55), virus-Ig complexes (18, 19), or virions not associated with LDL (2); however, it was previously shown that this population of virus particles was not highly infectious (5, 18, 19). Consistent with these findings, we found that these "intermediate-density" HCV particles did not bind MOLT-4 cells or allow coentry of alpha -sarcin.

We were unable to demonstrate a specific interaction between E2 and LDL or between E2 and the LDLr by using solid-phase immunoassays; therefore, the interaction between HCV and LDL remains unclear. A potential reason for this is that the recombinant E2 used in our experiments is truncated at the C terminus (deletion of 30 amino acids [positions 716 to 746] within the HCV polyprotein). Deletions in this region may result in conformational changes of the protein, leading to altered binding characteristics, or the LDL or LDLr binding domain could reside in this region of E2. The latter is unlikely, since this is a hydrophobic region that is unlikely to be highly surfaced exposed. An alternative explanation is that HCV binding to LDL or the LDLr may be mediated by viral proteins other than E2. Nonetheless, since several lines of evidence support an interaction between plasma LDL and HCV (2, 29), it seems reasonable to speculate that the LDL-HCV complex binds the LDLr by using the natural ligand (LDL), carrying HCV into the cell (2, 29). Our data support this hypothesis by demonstrating LDL-HCV colocalization by confocal microscopy and by density gradient centrifugation (55). The alpha -sarcin coentry experiments also reveal a correlation between LDLr expression and viral entry, further supporting data from other groups identifying the LDLr as the major means of HCV entry (2, 29). However, we were unable to block HCV binding to MOLT-4 cells completely with LDL; therefore, our data do not exclude the possibility that HCV may bind cells via additional cell surface proteins. Glycosaminoglycans (GAGs) are important in the cell surface binding of a number of microorganisms (37), including a number of viruses (herpesviruses, human immunodeficiency virus type 1, vaccinia virus, foot-and-mouth disease virus type O, and dengue virus) that bind to heparan sulfate on the cell surface (7, 9, 22, 33, 41). Although the role of proteoglycans in cell entry is unclear, recent reports suggest that HCV attachment may involve cell surface GAGs and possibly CD81 (17, 27, 34, 47). Virus-GAG interactions appear to be weak and reversible unless additional interactions occur, which may involve non-heparan sulfate virus entry receptors (37). Thus, it is possible that HCV or HCV-LDL complex attachment may be promoted by GAGs and that the LDLr is subsequently utilized for cell entry.


    ACKNOWLEDGMENTS

This work was supported by a Merit Review and a Career Development Enhancement Award from the Veterans Administration (J.T.S.), NIH grant RO1 AA12671 (J.T.S.), and NIH K08 A101460 (W.N.S.). In addition, The University of Iowa Flow Cytometry Core Program was utilized for these studies.

We thank Shoshana Levy, Stanford University, for providing murine and human soluble CD81. We also thank Douglas LaBrecque, Jinhua Xiang, James McCoy, and Donna Brashear for helpful discussions and the University of Iowa Digestive Diseases nursing staff for assistance with clinical samples.


    FOOTNOTES

* Corresponding author. Mailing address: Department of Internal Medicine, SW 54, GH, 200 Hawkins Dr., UIHC, Iowa City, IA 52242. Phone: (319) 356-3168. Fax: (319) 356-4600. E-mail: jack-stapleton{at}uiowa.edu.


    REFERENCES
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

1. Afonao, A. M. R., J. Jiang, F. Penin, C. Tareau, D. Samuel, M.-A. Petit, H. Bismuth, E. Dussaix, and C. Feray. 1999. Nonrandom distribution of hepatitis C virus quasispecies in plasma and peripheral blood mononuclear cells subsets. J. Virol. 73:9213-9221[Abstract/Free Full Text].
2. Agnello, V., G. Abel, M. Elfahal, G. B. Knight, and X. Zhang. 1999. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc. Natl. Acad. Sci. USA 96:12766-12771[Abstract/Free Full Text].
3. Agnello, V., R. T. Chung, and L. M. Kaplan. 1992. A role for hepatitis C virus infection in type II cryoglobulinemia. N. Engl. J. Med. 327:1490-1495[Abstract].
4. Bouffard, P., P. Hayashi, R. Acevedo, N. Levy, and J. Zeldis. 1992. Hepatitis C virus is detected in a monocyte/macrophage subpopulation of peripheral blood mononuclear cells of infected patients. J. Infect. Dis. 166:1276-1280[Medline].
5. Bradley, D. W., K. McCaustland, and E. H. Cook. 1985. Posttransfusion non-A, non-B hepatitis in chimpanzees: physicochemical evidence that the tubule forming agent is a small, enveloped virus. Gastroenterology 88:773-779[Medline].
6. Bradley, D. W., K. McCaustland, K. Krawcyznski, J. Spelbring, C. Humphrey, and E. H. Cook. 1991. Buoyant density of the factor CIII-derived isolate in sucrose. J. Med. Virol. 34:206-208[Medline].
7. Chen, Y., M. Maguire, R. E. Hileman, J. R. Fromm, J. D. Esko, R. Linhardt, and R. M. Marks. 1997. Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate. Nat. Med. 2:866-871.
8. Chomczynski, P., and N. Sacchi. 1987. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloraform extraction. Anal. Biochem. 162:156-159[Medline].
9. Chung, C., J. Hsiao, Y. Chang, and W. Chang. 1998. A27L protein mediates vaccinia virus interaction with cell surface heparan sulfate. J. Virol. 72:1577-1585[Abstract/Free Full Text].
10. Cribier, B., C. Schmitt, A. Bingen, A. Kirn, and F. Keller. 1995. In vitro infection of peripheral blood mononuclear cells by hepatitis C virus. J. Gen. Virol. 76:2485-2491[Abstract/Free Full Text].
11. Cuadras, M. A., C. F. Arias, and S. Lopez. 1997. Rotaviruses induce an early membrane permeabilization of MA104 cells and do not require a low intracellular Ca2+ concentration to initiate their replication cycle. J. Virol. 71:9065-9074[Abstract].
12. Cuthbert, J. A. 1994. Hepatitis C: progress and problems. Clin. Microbiol. Rev. 7:505-532[Abstract/Free Full Text].
13. Ferri, C., F. Greco, G. Longombardo, P. Palla, A. Moretti, E. Marzo, P. V. Fosella, G. Pasero, and S. Bombardieri. 1991. Antibodies against hepatitis C virus in mixed cryoglobulinemia patients. Infection 6:551-555.
14. Ferri, C., F. Greco, G. Longombardo, P. Pallo, A. Moretti, E. Marzo, A. Mazzoni, G. Pasero, S. Bombardieri, and R. Higuchi. 1991. Association between hepatitis C virus and mixed cryoglobulinemia. Clin. Exp. Rheumatol. 9:621-624[Medline].
15. Flint, M., J. M. Thomas, C. M. Maidens, C. Shotton, S. Levy, W. S. Barclay, and J. A. McKeating. 1999. Functional analysis of cell surface-expressed hepatitis C virus E2 glycoprotein. J. Virol. 73:6782-6790[Abstract/Free Full Text].
16. Fong, T. L., M. Shindo, S. M. Feinstone, J. Hoofnagle, and A. M. DiBisceglie. 1991. Detection of replicative intermediates of hepatitis C viral RNA in liver and serum of patients with chronic hepatitis C. J. Clin. Investig. 88:1058-1060.
17. Garson, J. A., D. Lubach, J. Passas, K. Whitby, and P. R. Grant. 1999. Suramin blocks hepatitis C binding to human hepatoma cells in vitro. J. Med. Virol. 57:238-242[CrossRef][Medline].
18. Han, J.-Q., W. N. Schmidt, P. Wu, P. Loh, G. Neil, D. R. LaBrecque, and J. T. Stapleton. 1997. Specific binding of hepatitis C virus to the Fc fragment of immunoglobulin molecules., p. 228-231. In M. Rizzeto, R. H. Purcell, J. L. Gerin, and G. Verme (ed.), Viral hepatitis and liver disease. Edizioni Minerva Medica, Turin, Italy.
19. Hijikata, M., Y. K. Shimizu, H. Katyo, A. Iwamoto, J. W. Shih, H. J. Alter, and R. H. Purcell. 1993. Equilibrium centrifugation studies of hepatitis C virus: evidence for circulating immune complexes. J. Virol. 67:1953-1958[Abstract/Free Full Text].
20. Hobbs, H. H., M. S. Brown, D. W. Russell, J. Davignon, and J. L. Goldstein. 1987. Deletion in the gene for the low-density-lipoprotein receptor in a majority of French Canadians with familial hypercholesterolemia. N. Engl. J. Med. 317:734-737[Abstract].
21. Hoofnagle, J. H. 1997. Hepatitis C: the clinical spectrum of disease. Hepatology 26:15S-20S[CrossRef][Medline].
22. Jackson, T., F. M. Ellard, R. A. Ghazaleh, S. M. Brookes, W. E. Blakemore, A. H. Corteyn, D. I. Stuart, J. W. Newman, and A. M. Q. King. 1996. Efficient infection of cells in culture by type O foot-and-mouth disease virus requires binding to cell surface heparan sulfate. J. Virol. 70:5282-5287[Abstract/Free Full Text].
23. Lanford, R. E., D. Chavez, F. V. Chisari, and C. Sureau. 1995. Lack of detection of negative-strand hepatitis C virus RNA in peripheral blood mononuclear cells and other extrahepatic tissues by the highly strand-specific rTth reverse transcriptase PCR. Virology 69:8079-8083.
24. Levy, S., S. C. Todd, and H. T. Maecker. 1998. CD81 (TAPA-1): a molecule involved in signal transduction and cell adhesion in the immune system. Annu. Rev. Immunol. 16:89-109[CrossRef][Medline].
25. Maecker, H. T., M. S. Do, and S. Levy. 1998. CD81 on B cells promotes interleukin 4 secretion and antibody production during T helper type 2 immune responses. Proc. Natl. Acad. Sci. USA 95:2458-2462[Abstract/Free Full Text].
26. Maecker, H. T., and S. Levy. 1997. Normal lymphocyte development but delayed humoral immune response in CD81-null mice. J. Exp. Med. 185:1505-1510[Abstract/Free Full Text].
27. Meola, A., A. Sbardellati, B. Bruni Ercole, M. Cerretani, M. Pezzanera, A. Ceccacci, A. Vitelli, S. Levy, A. Nicosia, C. Traboni, and E. Scarselli. 2000. Binding of hepatitis C virus E2 glycoprotein to CD81 does not correlate with species permissiveness to infection. J. Virol. 74:5933-5938[Abstract/Free Full Text].
28. Milne, R. W., R. Jr. Theolis, R. B. Verdery, and Y. L. Marcel. 1987. Characterization of monoclonal antibodies against human low density lipoprotein. Arteriosclerosis 3:23-30[Abstract/Free Full Text].
29. Monazahian, M., I. Bohme, S. Bonk, A. Koch, C. Scholz, S. Grethe, and R. Thomssen. 1999. Low-density lipoprotein receptor as a candidate receptor for hepatitis C virus. J. Med. Virol. 57:223-229[CrossRef][Medline].
30. Muller, H. M., E. Pfaff, T. Goeser, B. Kallinowski, C. Solbach, and L. Theillmann. 1993. Peripheral blood leukocytes serve as a possible extrahepatic site for hepatitis C virus replication. J. Gen. Virol. 74:669-676[Abstract/Free Full Text].
31. Munoz, A., J. L. Castrillo, and L. Carrasco. 1985. Modification of membrane permeability during Semliki Forest virus infection. Virology 146:203-212[CrossRef][Medline].
32. Otero, M. J., and L. Carrasco. 1987. Proteins are cointernalized with virion particles during early infection. Virology 160:75-80[CrossRef][Medline].
33. Patel, M., M. Yanagishita, G. Rodriguez, D. C. Bou-Habib, T. Oravecz, V. C. Hascall, and M. A. Norcross. 1993. Cell surface heparan sulfate proteoglycan mediates HIV-1 infection of T-cell lines. AIDS Res. Hum. Retroviruses 9:167-174[Medline].
34. Petracca, R., F. Falugi, G. Galli, N. Norais, D. Rosa, S. Campagnoli, V. Burgio, E. Di Stasio, B. Giardina, M. Houghton, S. Abrignani, and G. Gransi. 2000. Structure-function analysis of hepatitis C virus envelope-CD81 binding. J. Virol. 74:4824-4830[Abstract/Free Full Text].
35. Pileri, P., Y. Uematsu, S. Campagnoli, G. Galli, F. Falugi, R. Petracca, A. J. Weiner, M. Houghton, D. Rosa, G. Grandi, and S. Abrignani. 1998. Binding of hepatitis C virus to CD81. Science 282:938-941[Abstract/Free Full Text].
36. Prince, A. M., T. Huima-Byron, T. S. Parker, and M. M. Levine. 1996. Visualization of hepatitis C virions and putative defective interfering particles isolated from low-density lipoproteins. J. Viral Hepatol. 3:11-17[Medline].
37. Rostand, K. S., and J. D. Esko. 1997. Microbial adherence to and invasion through proteoglycans. Infect. Immun. 65:1-8[Medline].
38. Schmidt, W. N., D. Klinzman, D. LaBrecque, D. E. Macfarlane, and J. T. Stapleton. 1995. Direct detection of hepatitis C virus (HCV) RNA from whole blood, and comparison with HCV RNA in plasma and peripheral blood mononuclear cells. J. Med. Virol. 47:153-160[Medline].
39. Schmidt, W. N., J. T. Stapleton, D. R. LaBrecque, F. A. Mitros, K. Kirkegaard, M. J. P. Phillips, and D. Brashear. 2000. Hepatitis C infection and cryoglobulinemia: analysis of whole blood and plasma HCV RNA concentration and correlation with liver histology. Hepatology 31:737-744[CrossRef][Medline].
40. Schmidt, W. N., P. Wu, J.-Q. Han, M. J. Perino, D. R. LaBrecque, and J. T. Stapleton. 1997. Distribution of hepatitis C virus (HCV) RNA in whole blood and blood cell fractions: plasma HCV RNA analysis underestimates circulating virus load. J. Infect. Dis. 176:20-26[Medline].
41. Secchiero, P., D. Sun, A. L. DeVico, R. W. Crowley, M. S. Reitz, G. Zauli, P. Lusso, and R. C. Gallo. 1997. Role of the extracellular domain of human herpesvirus 7 glycoprotein B in virus binding to cell surface heparan sulfate proteoglycans. J. Virol. 71:4571-4585[Abstract].
42. Seipp, S., H. M. Mueller, E. Pfaff, W. Stremmel, L. Theilmann, and T. Goeser. 1997. Establishment of persistent hepatitis C virus infection and replication in vitro. J. Gen. Virol. 78:2467-2476[Abstract].
43. Shimizu, Y. K., S. M. Feinstone, M. Kohara, R. H. Purcell, and H. Yoshikura. 1996. Hepatitis C virus: detection of intracellular virus particles by electron microscopy. Hepatology 23:205-209[CrossRef][Medline].
44. Shimizu, Y. K., A. Iwamoto, M. Hijikata, R. H. Purcell, and H. Yoshikura. 1992. Evidence for in vitro replication of hepatitis C virus genome in a human T-cell line. Proc. Natl. Acad. Sci. USA 89:5477-5481[Abstract/Free Full Text].
45. Shimizu, Y. K., R. H. Purcell, and H. Yoshikura. 1993. Correlation between the infectivity of hepatitis C virus in vivo and its infectivity in vitro. Proc. Natl. Acad. Sci. USA 90:6037-6041[Abstract/Free Full Text].
46. Stapleton, J. T., D. Klinzman, W. N. Schmidt, P. Wu, D. R. LaBrecque, J.-Q. Han, M. J. Perino-Phillips, R. Woolson, and B. Alden. 1999. Prospective comparison of whole blood and plasma hepatitis C virus RNA detection systems: improved detection using whole blood as the source of viral RNA. J. Clin. Microbiol. 37:484-489[Abstract/Free Full Text].
47. Takikawa, S., K. Ishii, T. Suzuki, H. Asakura, Y. Matsuura, and T. Miyamura. 2000. Cell fusion activity of hepatitis C virus envelope-CD81 binding. J. Virol. 74:5066-5074[Abstract/Free Full Text].
48. Thomssen, R., S. Bonk, C. Propfe, K. H. Heermann, H. G. Kochel, and A. Uy. 1992. Association of hepatitis C virus in human sera with beta-lipoproteins. Med. Microbiol. Immunol. 181:293-300[CrossRef][Medline].
49. Thomssen, R., S. Bonk, and A. Thiele. 1993. Density heterogeneities of hepatitis C virus in human sera due to binding of beta-lipoproteins and immunoglobulins. Med. Microbiol. Immunol. 182:329-334[Medline].
50. Tong, M. J., N. S. el-Farra, A. R. Reikes, and R. L. Co. 1995. Clinical outcomes after transfusion-associated hepatitis C. N. Engl. J. Med. 332:1463-1466[Abstract/Free Full Text].
51. van Driel, I. R., J. L. Goldstein, T. C. Sudhof, and M. S. Brown. 1987. First cysteine-rich repeat in ligand-binding domain of low density lipoprotein receptor binds Ca2+ and monoclonal antibodies, but not lipoproteins. J. Biol. Chem. 262:17443-17449[Abstract/Free Full Text].
52. Wang, J. T., J. C. Sheu, J. T. Lin, T. H. Wang, and D. S. Chen. 1992. Detection of replicative form of hepatitis C virus RNA in peripheral blood mononuclear cells. J. Infect. Dis. 166:1167-1169[Medline].
53. Wünschmann, S., and J. T. Stapleton. 2000. Fluorescence-based quantitative methods for detecting human immunodeficiency virus type 1-induced syncytia. J. Clin. Microbiol. 38:3055-3060[Abstract/Free Full Text].
54. Xiang, J., K. J. Daniels, D. R. Soll, W. N. Schmidt, D. R. LaBrecque, and J. T. Stapleton. 1999. Visualization and characterization of GB virus C (hepatitis G virus) particles: evidence for a nucleocapsid. J. Viral Hepatol. 6:S16-S22[CrossRef].
55. Xiang, J., D. Klinzman, J. McLinden, W. N. Schmidt, D. R. LaBrecque, R. Gish, and J. T. Stapleton. 1998. Characterization of hepatitis G virus (GB-C virus) particles: evidence for a nucleocapsid and expression of sequences upstream of the E1 protein. J. Virol. 72:2738-2744[Abstract/Free Full Text].
56. Xiang, J., S. Wünschmann, W. N. Schmidt, J. Shao, and J. T. Stapleton. 2000. Full-length GB virus C (hepatitis G Virus) RNA transcripts are infectious in primary CD4-positive T cells. J. Virol. 74:9125-9133[Abstract/Free Full Text].

Journal of Virology, November 2000, p. 10055-10062, Vol. 74, No. 21
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Grove, J., Nielsen, S., Zhong, J., Bassendine, M. F., Drummer, H. E., Balfe, P., McKeating, J. A. (2008). Identification of a Residue in Hepatitis C Virus E2 Glycoprotein That Determines Scavenger Receptor BI and CD81 Receptor Dependency and Sensitivity to Neutralizing Antibodies. J. Virol. 82: 12020-12029 [Abstract] [Full Text]  
  • Meunier, J.-C., Russell, R. S., Engle, R. E., Faulk, K. N., Purcell, R. H., Emerson, S. U. (2008). Apolipoprotein C1 Association with Hepatitis C Virus. J. Virol. 82: 9647-9656 [Abstract] [Full Text]  
  • von Hahn, T., Rice, C. M. (2008). Hepatitis C Virus Entry. J. Biol. Chem. 283: 3689-3693 [Full Text]  
  • Molina, S., Castet, V., Pichard-Garcia, L., Wychowski, C., Meurs, E., Pascussi, J.-M., Sureau, C., Fabre, J.-M., SaCunha, A., Larrey, D., Dubuisson, J., Coste, J., McKeating, J., Maurel, P., Fournier-Wirth, C. (2008). Serum-Derived Hepatitis C Virus Infection of Primary Human Hepatocytes Is Tetraspanin CD81 Dependent. J. Virol. 82: 569-574 [Abstract] [Full Text]  
  • Tellinghuisen, T. L., Evans, M. J., von Hahn, T., You, S., Rice, C. M. (2007). Studying Hepatitis C Virus: Making the Best of a Bad Virus. J. Virol. 81: 8853-8867 [Full Text]  
  • Ryder, S. (2007). Do high lipids help clearance of hepatitis C?. Gut 56: 1044-1045 [Full Text]  
  • Petit, J.-M., Minello, A., Duvillard, L., Jooste, V., Monier, S., Texier, V., Bour, J.-B., Poussier, A., Gambert, P., Verges, B., Hillon, P. (2007). Cell surface expression of LDL receptor in chronic hepatitis C: correlation with viral load. Am. J. Physiol. Endocrinol. Metab. 293: E416-E420 [Abstract] [Full Text]  
  • Basu, A., Kanda, T., Beyene, A., Saito, K., Meyer, K., Ray, R. (2007). Sulfated Homologues of Heparin Inhibit Hepatitis C Virus Entry into Mammalian Cells. J. Virol. 81: 3933-3941 [Abstract] [Full Text]  
  • McLinden, J. H., Kaufman, T. M., Xiang, J., Chang, Q., Klinzman, D., Engel, A. M., Hess, G., Schmidt, U., Houghton, M., Stapleton, J. T. (2006). Characterization of an Immunodominant Antigenic Site on GB Virus C Glycoprotein E2 That Is Involved in Cell Binding. J. Virol. 80: 12131-12140 [Abstract] [Full Text]  
  • Xiang, J., McLinden, J. H., Chang, Q., Kaufman, T. M., Stapleton, J. T. (2006). An 85-aa segment of the GB virus type C NS5A phosphoprotein inhibits HIV-1 replication in CD4+ Jurkat T cells. Proc. Natl. Acad. Sci. USA 103: 15570-15575 [Abstract] [Full Text]  
  • Codran, A., Royer, C., Jaeck, D., Bastien-Valle, M., Baumert, T. F., Kieny, M. P., Pereira, C. A., Martin, J.-P. (2006). Entry of hepatitis C virus pseudotypes into primary human hepatocytes by clathrin-dependent endocytosis. J. Gen. Virol. 87: 2583-2593 [Abstract] [Full Text]  
  • Owsianka, A. M., Timms, J. M., Tarr, A. W., Brown, R. J. P., Hickling, T. P., Szwejk, A., Bienkowska-Szewczyk, K., Thomson, B. J., Patel, A. H., Ball, J. K. (2006). Identification of conserved residues in the e2 envelope glycoprotein of the hepatitis C virus that are critical for CD81 binding.. J. Virol. 80: 8695-8704 [Abstract] [Full Text]  
  • Zahn, A., Jennings, N., Ouwehand, W. H., Allain, J.-P. (2006). Hepatitis C virus interacts with human platelet glycoprotein VI.. J. Gen. Virol. 87: 2243-2251 [Abstract] [Full Text]  
  • Stuart, A. D., Brown, T. D. K. (2006). Entry of feline calicivirus is dependent on clathrin-mediated endocytosis and acidification in endosomes.. J. Virol. 80: 7500-7509 [Abstract] [Full Text]  
  • Koutsoudakis, G., Kaul, A., Steinmann, E., Kallis, S., Lohmann, V., Pietschmann, T., Bartenschlager, R. (2006). Characterization of the early steps of hepatitis C virus infection by using luciferase reporter viruses.. J. Virol. 80: 5308-5320 [Abstract] [Full Text]  
  • Cocquerel, L., Voisset, C., Dubuisson, J. (2006). Hepatitis C virus entry: potential receptors and their biological functions.. J. Gen. Virol. 87: 1075-1084 [Abstract] [Full Text]  
  • Price, D A, Bassendine, M F, Norris, S M, Golding, C, Toms, G L, Schmid, M L, Morris, C M, Burt, A D, Donaldson, P T (2006). Apolipoprotein {varepsilon}3 allele is associated with persistent hepatitis C virus infection. Gut 55: 715-718 [Abstract] [Full Text]  
  • Nielsen, S. U., Bassendine, M. F., Burt, A. D., Martin, C., Pumeechockchai, W., Toms, G. L. (2006). Association between Hepatitis C Virus and Very-Low-Density Lipoprotein (VLDL)/LDL Analyzed in Iodixanol Density Gradients. J. Virol. 80: 2418-2428 [Abstract] [Full Text]  
  • Yamada, E., Montoya, M., Schuettler, C. G., Hickling, T. P., Tarr, A. W., Vitelli, A., Dubuisson, J., Patel, A. H., Ball, J. K., Borrow, P. (2005). Analysis of the binding of hepatitis C virus genotype 1a and 1b E2 glycoproteins to peripheral blood mononuclear cell subsets. J. Gen. Virol. 86: 2507-2512 [Abstract] [Full Text]  
  • Martin, F., Roth, D. M., Jans, D. A., Pouton, C. W., Partridge, L. J., Monk, P. N., Moseley, G. W. (2005). Tetraspanins in Viral Infections: a Fundamental Role in Viral Biology?. J. Virol. 79: 10839-10851 [Full Text]  
  • Zahn, A., Allain, J.-P. (2005). Hepatitis C virus and hepatitis B virus bind to heparin: purification of largely IgG-free virions from infected plasma by heparin chromatography. J. Gen. Virol. 86: 677-685 [Abstract] [Full Text]  
  • Steinmann, D., Barth, H., Gissler, B., Schurmann, P., Adah, M. I., Gerlach, J. T., Pape, G. R., Depla, E., Jacobs, D., Maertens, G., Patel, A. H., Inchauspe, G., Liang, T. J., Blum, H. E., Baumert, T. F. (2004). Inhibition of Hepatitis C Virus-Like Particle Binding to Target Cells by Antiviral Antibodies in Acute and Chronic Hepatitis C. J. Virol. 78: 9030-9040 [Abstract] [Full Text]  
  • Keck, Z.-Y., Op De Beeck, A., Hadlock, K. G., Xia, J., Li, T.-K., Dubuisson, J., Foung, S. K. H. (2004). Hepatitis C Virus E2 Has Three Immunogenic Domains Containing Conformational Epitopes with Distinct Properties and Biological Functions. J. Virol. 78: 9224-9232 [Abstract] [Full Text]  
  • McKeating, J. A., Zhang, L. Q., Logvinoff, C., Flint, M., Zhang, J., Yu, J., Butera, D., Ho, D. D., Dustin, L. B., Rice, C. M., Balfe, P. (2004). Diverse Hepatitis C Virus Glycoproteins Mediate Viral Infection in a CD81-Dependent Manner. J. Virol. 78: 8496-8505 [Abstract] [Full Text]  
  • Heo, T.-H., Chang, J.-H., Lee, J.-W., Foung, S. K. H., Dubuisson, J., Kang, C.-Y. (2004). Incomplete Humoral Immunity against Hepatitis C Virus Is Linked with Distinct Recognition of Putative Multiple Receptors by E2 Envelope Glycoprotein. J. Immunol. 173: 446-455 [Abstract] [Full Text]  
  • Op De Beeck, A., Voisset, C., Bartosch, B., Ciczora, Y., Cocquerel, L., Keck, Z., Foung, S., Cosset, F.-L., Dubuisson, J. (2004). Characterization of Functional Hepatitis C Virus Envelope Glycoproteins. J. Virol. 78: 2994-3002 [Abstract] [Full Text]  
  • Zhang, J., Randall, G., Higginbottom, A., Monk, P., Rice, C. M., McKeating, J. A. (2004). CD81 Is Required for Hepatitis C Virus Glycoprotein-Mediated Viral Infection. J. Virol. 78: 1448-1455 [Abstract] [Full Text]  
  • Barth, H., Schafer, C., Adah, M. I., Zhang, F., Linhardt, R. J., Toyoda, H., Kinoshita-Toyoda, A., Toida, T., van Kuppevelt, T. H., Depla, E., von Weizsacker, F., Blum, H. E., Baumert, T. F. (2003). Cellular Binding of Hepatitis C Virus Envelope Glycoprotein E2 Requires Cell Surface Heparan Sulfate. J. Biol. Chem. 278: 41003-41012 [Abstract] [Full Text]  
  • Cocquerel, L., Kuo, C.-C., Dubuisson, J., Levy, S. (2003). CD81-Dependent Binding of Hepatitis C Virus E1E2 Heterodimers. J. Virol. 77: 10677-10683 [Abstract] [Full Text]  
  • Balasubramanian, A., Ganju, R. K., Groopman, J. E. (2003). Hepatitis C Virus and HIV Envelope Proteins Collaboratively Mediate Interleukin-8 Secretion through Activation of p38 MAP Kinase and SHP2 in Hepatocytes. J. Biol. Chem. 278: 35755-35766 [Abstract] [Full Text]  
  • Hsu, M., Zhang, J., Flint, M., Logvinoff, C., Cheng-Mayer, C., Rice, C. M., McKeating, J. A. (2003). Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc. Natl. Acad. Sci. USA 100: 7271-7276 [Abstract] [Full Text]  
  • Dolganiuc, A., Kodys, K., Kopasz, A., Marshall, C., Do, T., Romics, L. Jr., Mandrekar, P., Zapp, M., Szabo, G. (2003). Hepatitis C Virus Core and Nonstructural Protein 3 Proteins Induce Pro- and Anti-inflammatory Cytokines and Inhibit Dendritic Cell Differentiation. J. Immunol. 170: 5615-5624 [Abstract] [Full Text]  
  • Pohlmann, S., Zhang, J., Baribaud, F., Chen, Z., Leslie, G. J., Lin, G., Granelli-Piperno, A., Doms, R. W., Rice, C. M., McKeating, J. A. (2003). Hepatitis C Virus Glycoproteins Interact with DC-SIGN and DC-SIGNR. J. Virol. 77: 4070-4080 [Abstract] [Full Text]  
  • Cocquerel, L., Quinn, E. R., Flint, M., Hadlock, K. G., Foung, S. K. H., Levy, S. (2002). Recognition of Native Hepatitis C Virus E1E2 Heterodimers by a Human Monoclonal Antibody. J. Virol. 77: 1604-1609 [Abstract] [Full Text]  
  • Drummer, H. E., Wilson, K. A., Poumbourios, P. (2002). Identification of the Hepatitis C Virus E2 Glycoprotein Binding Site on the Large Extracellular Loop of CD81. J. Virol. 76: 11143-11147 [Abstract] [Full Text]  
  • Triyatni, M., Saunier, B., Maruvada, P., Davis, A. R., Ulianich, L., Heller, T., Patel, A., Kohn, L. D., Liang, T. J. (2002). Interaction of Hepatitis C Virus-Like Particles and Cells: a Model System for Studying Viral Binding and Entry. J. Virol. 76: 9335-9344 [Abstract] [Full Text]  
  • Hilgard, P., Huang, T., Wolkoff, A. W., Stockert, R. J. (2002). Translated Alu sequence determines nuclear localization of a novel catalytic subunit of casein kinase 2. Am. J. Physiol. Cell Physiol. 283: C472-C483 [Abstract] [Full Text]  
  • Clayton, R. F., Owsianka, A., Aitken, J., Graham, S., Bhella, D., Patel, A. H. (2002). Analysis of Antigenicity and Topology of E2 Glycoprotein Present on Recombinant Hepatitis C Virus-Like Particles. J. Virol. 76: 7672-7682 [Abstract] [Full Text]  
  • Andre, P., Komurian-Pradel, F., Deforges, S., Perret, M., Berland, J. L., Sodoyer, M., Pol, S., Brechot, C., Paranhos-Baccala, G., Lotteau, V. (2002). Characterization of Low- and Very-Low-Density Hepatitis C Virus RNA-Containing Particles. J. Virol. 76: 6919-6928 [Abstract] [Full Text]  
  • Lambot, M., Fretier, S., De Beeck, A. O., Quatannens, B., Lestavel, S., Clavey, V., Dubuisson, J. (2002). Reconstitution of Hepatitis C Virus Envelope Glycoproteins into Liposomes as a Surrogate Model to Study Virus Attachment. J. Biol. Chem. 277: 20625-20630 [Abstract] [Full Text]  
  • Meyer, K., Basu, A., Przysiecki, C. T., Lagging, L. M., Di Bisceglie, A. M., Conley, A. J., Ray, R. (2002). Complement-Mediated Enhancement of Antibody Function for Neutralization of Pseudotype Virus Containing Hepatitis C Virus E2 Chimeric Glycoprotein. J. Virol. 76: 2150-2158 [Abstract] [Full Text]  
  • Wellnitz, S., Klumpp, B., Barth, H., Ito, S., Depla, E., Dubuisson, J., Blum, H. E., Baumert, T. F. (2002). Binding of Hepatitis C Virus-Like Particles Derived from Infectious Clone H77C to Defined Human Cell Lines. J. Virol. 76: 1181-1193 [Abstract] [Full Text]  
  • Yeh, C.-T., Lai, H.-Y., Chen, T.-C., Chu, C.-M., Liaw, Y.-F. (2001). Identification of a Hepatic Factor Capable of Supporting Hepatitis C Virus Replication in a Nonpermissive Cell Line. J. Virol. 75: 11017-11024 [Abstract] [Full Text]  
  • Xiang, J., Wunschmann, S., Diekema, D. J., Klinzman, D., Patrick, K. D., George, S. L., Stapleton, J. T. (2001). Effect of Coinfection with GB Virus C on Survival among Patients with HIV Infection. NEJM 345: 707-714 [Abstract] [Full Text]  
  • Owsianka, A., Clayton, R. F., Loomis-Price, L. D., McKeating, J. A., Patel, A. H. (2001). Functional analysis of hepatitis C virus E2 glycoproteins and virus-like particles reveals structural dissimilarities between different forms of E2. J. Gen. Virol. 82: 1877-1883 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wünschmann, S.
Right arrow Articles by Stapleton, J. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wünschmann, S.
Right arrow Articles by Stapleton, J. T.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»